Myelodysplasia-associated Mutations in Serine/arginine-rich Splicing Factor SRSF2 Lead to Alternative Splicing of CDC25C

Overview

Journal BMC Mol Biol

Publisher Biomed Central

Specialty Molecular Biology

Date 2016 Aug 25

PMID 27552991

Citations 5

Authors

Lindsey Skrdlant

Jeremy M Stark

Ren-Jang Lin

Affiliations

Soon will be listed here.

Abstract

Background: Serine-arginine rich splicing factor 2 (SRSF2) is a protein known for its role in RNA splicing and genome stability. It has been recently discovered that SRSF2, along with other splicing regulators, is frequently mutated in patients with myelodysplastic syndrome (MDS). The most common MDS mutations in SRSF2 occur at proline 95; the mutant proteins are shown to have different RNA binding preferences, which may contribute to splicing changes detected in mutant cells. However, the influence of these SRSF2 MDS-associated mutations on specific splicing events remains poorly understood.

Results: A tetracycline-inducible TF-1 erythroleukemia cell line was transduced with retroviruses to create cell lines expressing HA-tagged wildtype SRSF2, SRSF2 with proline 95 point mutations found in MDS, or SRSF2 with a deletion of one of the four major domains of the protein. Effects of these mutants on apoptosis and specific alternative splicing events were evaluated. Cells were also treated with DNA damaging drugs for comparison. MDS-related P95 point mutants of SRSF2 were expressed and phosphorylated at similar levels as wildtype SRSF2. However, cells expressing mutant SRSF2 exhibited higher levels of apoptosis than cells expressing wildtype SRSF2. Regarding alternative splicing events, in nearly all examined cases, SRSF2 P95 mutants acted in a similar fashion as the wildtype SRSF2. However, cells expressing SRSF2 P95 mutants had a percent increase in the C5 spliced isoform of cell division cycle 25C (CDC25C). The same alternative splicing of CDC25C was detected by treating cells with DNA damaging drugs, such as cisplatin, camptothecin, and trichostatin A at appropriate dosage. However, unlike DNA damaging drugs, SRSF2 P95 mutants did not activate the Ataxia telangiectasia mutated (ATM) pathway.

Conclusion: SRSF2 P95 mutants lead to alternative splicing of CDC25C in a manner that is not dependent on the DNA damage response.

Citing Articles

SRSFs mediate the function of AR in the ovarian granulosa cells of patients with PCOS.

Luo J, Ye H, Hao L, Sun Y, Li R, Li Y Genes Dis. 2021; 8(1):94-109.

PMID: 33569518 PMC: 7859457. DOI: 10.1016/j.gendis.2019.09.005.

RNA-binding proteins in tumor progression.

Qin H, Ni H, Liu Y, Yuan Y, Xi T, Li X J Hematol Oncol. 2020; 13(1):90.

PMID: 32653017 PMC: 7353687. DOI: 10.1186/s13045-020-00927-w.

Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia.

Bamopoulos S, Batcha A, Jurinovic V, Rothenberg-Thurley M, Janke H, Ksienzyk B Leukemia. 2020; 34(10):2621-2634.

PMID: 32358566 DOI: 10.1038/s41375-020-0839-4.

Myeloid Disease Mutations of Splicing Factor SRSF2 Cause G2-M Arrest and Skewed Differentiation of Human Hematopoietic Stem and Progenitor Cells.

Bapat A, Keita N, Martelly W, Kang P, Seet C, Jacobsen J Stem Cells. 2018; 36(11):1663-1675.

PMID: 30004607 PMC: 6283046. DOI: 10.1002/stem.2885.

Differential Impacts of Alternative Splicing Networks on Apoptosis.

Lin J, Tsao M, Lin Y Int J Mol Sci. 2016; 17(12).

PMID: 27983653 PMC: 5187897. DOI: 10.3390/ijms17122097.

References

Ilagan J, Ramakrishnan A, Hayes B, Murphy M, Zebari A, Bradley P . U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res. 2014; 25(1):14-26. PMC: 4317169. DOI: 10.1101/gr.181016.114. View

Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge S . Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci U S A. 2000; 97(19):10389-94. PMC: 27034. DOI: 10.1073/pnas.190030497. View

Caudill J, Porcher J, Steensma D . Aberrant pre-mRNA splicing of a highly conserved cell cycle regulator, CDC25C, in myelodysplastic syndromes. Leuk Lymphoma. 2008; 49(5):989-93. DOI: 10.1080/10428190801971690. View

Wegener S, Hampe W, Herrmann D, Schaller H . Alternative splicing in the regulatory region of the human phosphatases CDC25A and CDC25C. Eur J Cell Biol. 2001; 79(11):810-5. DOI: 10.1078/0171-9335-00115. View

Fu X, Maniatis T . The 35-kDa mammalian splicing factor SC35 mediates specific interactions between U1 and U2 small nuclear ribonucleoprotein particles at the 3' splice site. Proc Natl Acad Sci U S A. 1992; 89(5):1725-9. PMC: 48525. DOI: 10.1073/pnas.89.5.1725. View

Gersuk G, Beckham C, Loken M, Kiener P, Anderson J, FARRAND A . A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol. 1998; 103(1):176-88. DOI: 10.1046/j.1365-2141.1998.00933.x. View

Zhang J, Lieu Y, Ali A, Penson A, Reggio K, Rabadan R . Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities. Proc Natl Acad Sci U S A. 2015; 112(34):E4726-34. PMC: 4553800. DOI: 10.1073/pnas.1514105112. View

Mu X, Jin X, Farnham M, Li Y, ONeill C . DNA damage-sensing kinases mediate the mouse 2-cell embryo's response to genotoxic stress. Biol Reprod. 2011; 85(3):524-35. DOI: 10.1095/biolreprod.110.089334. View

Wang C, Chua K, Seghezzi W, Lees E, Gozani O, REED R . Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis. Genes Dev. 1998; 12(10):1409-14. PMC: 316838. DOI: 10.1101/gad.12.10.1409. View

10.

Chaturvedi P, Eng W, Zhu Y, Mattern M, Mishra R, Hurle M . Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene. 1999; 18(28):4047-54. DOI: 10.1038/sj.onc.1202925. View

11.

Ryan A, Squires S, Strutt H, Johnson R . Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res. 1991; 19(12):3295-300. PMC: 328325. DOI: 10.1093/nar/19.12.3295. View

12.

Albert H, Battaglia E, Monteiro C, Bagrel D . Genotoxic stress modulates CDC25C phosphatase alternative splicing in human breast cancer cell lines. Mol Oncol. 2012; 6(5):542-52. PMC: 5528395. DOI: 10.1016/j.molonc.2012.06.003. View

13.

Colton S, Xu X, Wang Y, Wang G . The involvement of ataxia-telangiectasia mutated protein activation in nucleotide excision repair-facilitated cell survival with cisplatin treatment. J Biol Chem. 2006; 281(37):27117-25. DOI: 10.1074/jbc.M602826200. View

14.

Jadersten M, Karsan A . Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring. Haematologica. 2011; 96(2):177-80. PMC: 3031681. DOI: 10.3324/haematol.2010.038281. View

15.

Ma X, Does M, Raza A, Mayne S . Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007; 109(8):1536-42. DOI: 10.1002/cncr.22570. View

16.

Ngo J, Chakrabarti S, Ding J, Velazquez-Dones A, Nolen B, Aubol B . Interplay between SRPK and Clk/Sty kinases in phosphorylation of the splicing factor ASF/SF2 is regulated by a docking motif in ASF/SF2. Mol Cell. 2005; 20(1):77-89. DOI: 10.1016/j.molcel.2005.08.025. View

17.

Banin S, Moyal L, Shieh S, Taya Y, Anderson C, Chessa L . Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 1998; 281(5383):1674-7. DOI: 10.1126/science.281.5383.1674. View

18.

Kongruttanachok N, Phuangphairoj C, Thongnak A, Ponyeam W, Rattanatanyong P, Pornthanakasem W . Replication independent DNA double-strand break retention may prevent genomic instability. Mol Cancer. 2010; 9:70. PMC: 2867818. DOI: 10.1186/1476-4598-9-70. View

19.

Matsuda K, Ishida F, Ito T, Nakazawa H, Miura S, Taira C . Spliceosome-related gene mutations in myelodysplastic syndrome can be used as stable markers for monitoring minimal residual disease during follow-up. Leuk Res. 2012; 36(11):1393-7. DOI: 10.1016/j.leukres.2012.07.019. View

20.

Lyons A, Blake S, Doherty K . Flow cytometric analysis of cell division by dilution of CFSE and related dyes. Curr Protoc Cytom. 2013; Chapter 9:9.11.1-9.11.12. DOI: 10.1002/0471142956.cy0911s64. View